Robert Brown: Hemostatic Factors in Recurrent Pregnancy Loss
Robert Brown, Academic Obstetrician, shared a post on LinkedIn:
“Recurrent Pregnancy Loss.
Evaluation of recurrent pregnancy loss is indicated after two or three consecutive miscarriages.
The minimum diagnostic work-up consists of a complete medical, surgical, genetic, and family history and a physical examination.
The history should include a description of the gestational age and characteristics of all previous pregnancies.
Physical examination should include a general physical examination with attention to signs of endocrinopathy(hirsutism, galactorrhea) and pelvic organ abnormalities.
Laboratory and imaging tests include: sonohysterogram, testing for antiphospholipid syndrome (ACA antibodies and lupus anticoagulant performed twice twelve weeks apart).
The diagnosis should include anti-beta2glycoprotein I antibodies as well.
TSH and thyroid perixidase antibodies, parental karyotype and karyotype of the abortus if the above examinations are normal.
This is the last test performed only if preceding work-up is yields negative results.
Additional tests depend upon the diagnosis suggested by history, physical examination, and laboratory results.
Male contribution to RPL is unclear.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin